Option Care Health jumped 22% on a deal nobody has signed

Shares of Option Care Health climbed about 22% in Monday's after-hours session and held most of that move into Tuesday's pre-market, quoted between 21.3% and 23.8% higher at around $28.94. There is no transaction to point to. What there is instead is a Financial Times report, published Monday afternoon and sourced to people familiar with the matter, that the largest independent provider of home and alternate-site infusion services in the United States is in advanced talks to sell itself.

The bidders named in the report are an unusual pair: McKesson, one of the three drug distributors that move most of the medicine in the country, and Clayton Dubilier & Rice, a private equity firm with a long record in healthcare services. The reported valuation is more than $5 billion including debt.

The structure is the interesting part

On the terms described to the FT, CD&R would own 51% of Option Care through a joint venture and McKesson 49%, with McKesson holding a right to purchase the buyout firm's stake at a later date. None of the three companies has confirmed the talks; McKesson declined to comment.

That split is not an accident of financing. A distributor taking majority control of a large provider of the therapies it distributes invites a particular kind of scrutiny, both from antitrust reviewers and from the hospital systems and payers on the other side of its contracts. Starting as a minority partner, with a path to full ownership once the business has been run for a few years under someone else's control, is a structure that buys time on both fronts.

It also spreads the cheque. McKesson is a company with roughly $400 billion in annual revenue, so a $5 billion deal is not a stretch; sharing it with a financial sponsor is about appetite and optics rather than capacity.

What McKesson would be buying

Option Care gives patients intravenous medicines at home or in standalone infusion suites rather than in a hospital outpatient department. That is the part of the system payers have spent a decade trying to grow, because the same drug administered at home generally costs them less than the same drug administered in a hospital.

For McKesson it would be a step down the chain. Today it distributes specialty drugs to the clinics and practices that administer them. Owning a stake in Option Care would put it inside the administration step itself, alongside the oncology and multispecialty clinic network it has been building. The company has been moving in that direction for a while: in August it agreed to buy Precision Medicine Group, a clinical research and drug-commercialization business, for about $2.25 billion.

The seller's side of it

The bid arrives after a soft stretch. Option Care reported second-quarter revenue of $1.44 billion, up 1.9% from a year earlier — growth that is slow for a company in a category that is supposed to be expanding — and in late July narrowed full-year guidance to $5.675 billion to $5.775 billion of revenue and adjusted earnings of $1.85 to $1.92 a share. Management attributed part of the pressure to one long-running therapy, while short-duration infusions and some rare-disease treatments held up.

A business growing below 2% in a structurally growing market is the kind of asset private equity looks at closely, on the theory that the problem is operational rather than terminal.

What is actually known, and what is not

It is worth separating the two. Known: the FT reported advanced talks, a reported valuation above $5 billion including debt, a 51/49 split with an option, and a possible agreement as soon as Tuesday. Not known: whether any of it gets signed. The FT itself said the talks could still fall apart, and none of the three parties has said anything on the record.

That gap is what a 22% move on an unconfirmed report represents — the market assigning a high probability to a transaction that does not yet exist. Deals at this stage do get announced, and they also get leaked and then abandoned. Monday's move prices the first outcome; the second one has happened to plenty of companies whose shares spiked on a Friday report and gave it back the following week.

Why it matters beyond one ticker

This is the third sizable healthcare services transaction in recent weeks, and it fits the same pattern as the others: buyers are paying for care delivered outside the hospital. Monday's broader tape was lifted by two other buyouts entirely — Schneider Electric's agreement to acquire PTC and C.H. Robinson's offer for RXO — in a session where dealmaking, not data, set the tone.

If the Option Care agreement does land, it will be the second multibillion-dollar McKesson acquisition in two months and a test of how regulators view a distributor taking an economic interest in the point of care. If it does not, Tuesday's premium is a reminder of what an unconfirmed report is worth.